Expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (HRPC) previously treated with unlimited cytotoxic chemotherapy regimen (SPERA)

Trial Profile

Expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (HRPC) previously treated with unlimited cytotoxic chemotherapy regimen (SPERA)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2012

At a glance

  • Drugs Prednisone; Satraplatin
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SPERA
  • Most Recent Events

    • 08 May 2012 Actual patient number is 344 according to ClinicalTrials.gov.
    • 08 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top